Mediwound Ltd (MDWD) reported quarterly earnings results on Thursday, Apr-21-2016. The company said it had a profit of $-0.17 Earnings per Share for the quarter. The results exceeded Wall Street expectations beating the analyst consensus estimate by $0.07. Analysts had a consensus of $-0.24. The company posted revenue of $.25 million in the period, compared to analysts expectations of $.28 million. The company’s revenue was up 279.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.30 EPS.
Mediwound Ltd opened for trading at $7.9 and hit $8.24 on the upside on Monday, eventually ending the session at $8.16, with a gain of 1.49% or 0.12 points. The heightened volatility saw the trading volume jump to 2,84,880 shares. Company has a market cap of $178 M.
MediWound Ltd. is a fully integrated biopharmaceutical company. The Company is focused on developing manufacturing and commercializing products to address unmet needs in the fields of severe burns chronic and other hard-to-heal wounds and connective tissue disorders. The Companys biopharmaceutical product NexoBrid which is based on its patented proteolytic enzyme technology represents a new paradigm in burn care management and its clinical trials have demonstrated with statistical significance its ability to non-surgically and rapidly remove the eschar earlier upon patient admission without harming viable tissues. The Company launched NexoBrid in December 2013 in the European Union through its wholly-owned German subsidiary targeting a focused audience of burn specialists treating patients in burn centers and hospital burn units.